MedTrace Logo

Treatment for Post Acute COVID-19 Syndrome

NCT05507372 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2022-08-22

No results posted yet for this study

Summary

Post-acute COVID-19 tinnitus has not been treated successfully. As tinnitus may be related to SARS-CoV-2 neurological manifestations. This study aims to investigate if the dopamine receptor antagonists can be used effectively treat COVID-19 induced tinnitus.

Conditions

  • Tinnitus, Subjective

Interventions

DRUG

Pimozide 1 MG

Dopamine Receptor Antagonist - Oral Pimozide

Sponsors & Collaborators

  • Jupiter Wellness, Inc.

    collaborator UNKNOWN

  • Applied Biology, Inc.

    lead INDUSTRY

Principal Investigators

  • RAHUL RAJENDRA KUNKULOL, MBBS · DEPT.OF PHARMACOLOGY, RURAL MEDICAL COLLEGE, PIMS- DU (DU), LONI, PIN: 413736

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-10-01
Primary Completion
2023-06-01
Completion
2023-12-01

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05507372 on ClinicalTrials.gov